Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Csl Ltd ADR (OP:CSLLY)

58.26 -0.52 (-0.88%)
Streaming Delayed Price Updated: 10:16 AM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Csl Ltd ADR

< Previous 1 2 Next >
News headline image
Flu Season's Here—This Dividend-Payer Controls the Shot Market ↗
Via MarketBeat
Topics Artificial Intelligence Death
News headline image
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder ↗
FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients. 
Via Benzinga
News headline image
How KalVista Pharma Is Taking On A Rare But Deadly Disease ↗
The company is working on the first new on-demand treatment for hereditary angioedema in 11 years. 
Via Investor's Business Daily
News headline image
European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Life Sciences Investor Forum: Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years ↗
CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating prophylaxis need for most patients at year four. 
Via Benzinga
News headline image
CSL Behring Scales Global HCP Engagement and Attracts new HCPs with the ON24 Platform
From ON24
Via Business Wire
News headline image
Life Sciences Investor Forum Agenda Announced for June 11th-12th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Trial 
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report ↗
The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5... 
Via Benzinga
News headline image
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses ↗
CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity compared to Pfizer's Comirnaty in a Phase 3 study, persisting for one year and at a... 
Via Benzinga
News headline image
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
CSL Joins Accumulus Synergy to Drive Industry Change
Following the launch of Accumulus Synergy’s innovative cloud-based information exchange platform, CSL joins the nonprofit industry association 
From Accumulus Synergy
Via GlobeNewswire
News headline image
Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
From CSL Behring
Via GlobeNewswire
News headline image
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
From Arcturus Therapeutics
Via Business Wire
News headline image
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia ↗
FDA approves Pfizer's Beqvez for adults with hemophilia B, offering a one-time treatment to produce FIX. Experience reduced bleeding frequency. Explore Pfizer's warranty program. 
Via Benzinga
News headline image
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia 
Via MarketBeat
News headline image
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
From Arcturus Therapeutics
Via Business Wire
News headline image
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
From Arcturus Therapeutics
Via Business Wire
News headline image
Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside ↗
Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space. 
Via Benzinga
News headline image
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? ↗
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
News headline image
Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in... 
From Cara Therapeutics, Inc.
Via GlobeNewswire
News headline image
OTC Markets Group Welcomes CSL Limited to OTCQX
From OTC Markets
Via GlobeNewswire
News headline image
5 Diverse Medical Stocks To Buy For 2023 And Beyond ↗
Healthcare will always be essential to society, making many health companies viable investments for growth. A look at the five top-rated stocks that investors may want to consider buying for 2023 and... 
Via Talk Markets
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.